Meeting
2022 ASCO Annual Meeting
Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors.
Presenter
Meredith McKean, MD
Sarah Cannon Research Institute, Tennessee Oncology, PLLC
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03611868
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9517)
DOI
10.1200/JCO.2022.40.16_suppl.9517
Abstract #
9517
Poster Bd #
110
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2021 ASCO Annual Meeting
Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs.
Speaker: Anthony W. Tolcher, MD, FASCO
Speaker: David F. McDermott, MD
Videos & Slides
2021 ASCO Annual Meeting
Targeting innate immunity with BXCL701 in combination with pembrolizumab in patients with advanced solid cancers: Phase 2 basket study.
Speaker: Ozgur Karakuzu, MSc, PhD
Videos & Slides
2024 ASCO Annual Meeting
Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study.
Speaker: Carlos Rojas, MD